StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30243% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Cancidas (caspofungin, legacy) by Quarter

Cancidas (caspofungin, legacy) — International sales ($M) ($M)

QuarterlyAnnual

Merck Cancidas (caspofungin, legacy): $35M in Q4 2022, down 20.5% from a year earlier. That is the lowest of the 25 quarters on record here. No newer figure appears in the documents we track.

Latest, Q4 2022
35
Period ended Dec 31, 2022
Change on a year earlier
-20.5%
44 in Q4 2021
History
25 quarters
Since Q4 2016
Sources
17
Documents cited below

Where the Q4 2022 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (filed 2023-02-24) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCancidas (caspofungin, legacy) — International sales ($M) ($M)Year on yearSource
Q4 2022Dec 31, 202235-20.5%Form 10-K (filed 2023-02-24) ↗
Q3 2022Sep 30, 202242-25.0%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2022Jun 30, 202239-26.4%Form 8-K (tm2221828d1_ex99-1.htm, filed 2022-07-28) ↗
Q1 2022Mar 31, 202252-5.5%Form 8-K (tm2213615d1_ex99-1.htm, filed 2022-04-28) ↗
Q4 2021Dec 31, 202144-26.7%Form 10-K (filed 2023-02-24) ↗
Q3 2021Sep 30, 202156+14.3%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2021Jun 30, 202153+17.8%Form 8-K (tm2221828d1_ex99-1.htm, filed 2022-07-28) ↗
Q1 2021Mar 31, 202155+5.8%Form 8-K (tm2213615d1_ex99-1.htm, filed 2022-04-28) ↗
Q4 2020Dec 31, 202060+7.1%Form 10-K (filed 2023-02-24) ↗
Q3 2020Sep 30, 202049-21.0%Form 8-K (tm2131077d1_ex99-1.htm, filed 2021-10-28) ↗
Q2 2020Jun 30, 202045-29.7%Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2020Mar 31, 202052-13.3%Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q4 2019Dec 31, 201956-16.4%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q3 2019Sep 30, 201962-19.5%Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2019Jun 30, 201964-22.9%Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2019Mar 31, 201960-31.8%Form 8-K (tm2016917d1_ex99-1.htm, filed 2020-04-28) ↗

Breakdown

What makes up cancidas (caspofungin, legacy)

Cite this data

StockData. (2026). Merck Cancidas (caspofungin, legacy) ($M), quarterly Q4 2016–Q4 2022 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-cancidas-intl

See every metric in the Merck KPI table. Data updated Oct 26, 2026.

See a number that looks wrong?